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Aims Statin therapy is associated with important benefits for patients at risk of, and with, established cardiovascular disease.
There is widespread interest in whether intensive dosing of statins yields larger treatment effects. We aimed to deter-
mine if intensive dosing is clinically important using a meta-analysis of randomized clinical trials (RCTs).
Methods We conducted comprehensive searches of electronic databases from inception to December 2010. We included any
RCT evaluating a larger dose with a clinically common dose. Two reviewers independently extracted data, in dupli-
cate. We performed random-effects meta-analysis and a trial sequential analysis.
Results We identified 10 RCTs enrolling a total of 41 778 participants. Trials followed patients for a mean of 2.5 years. We
did not find statistically significant effects on all-cause mortality [relative risk (RR) 0.92, 95% confidence interval (CI),
0.83–1.03, P ¼ 0.14, I2 ¼ 38%] or cardiovascular disease (CVD) deaths (RR 0.89, 95% CI, 0.78–1.01, P ¼ 0.07,
I2 ¼ 34%). When we pooled the composite endpoint of coronary heart disease (CHD) death plus non-fatal myocar-
dial infarction (MI), we found a significant protective effect of intensive statin dosing (RR 0.90, 95% CI, 0.84–0.96,
P ≤ 0.0001, I2 ¼ 0%). We also found a significant effect on non-fatal MIs (RR 0.82, 95% CI, 0.76–0.89, P ≤ 0.0001,
I2 ¼ 0%) and a significant reduction in the composite of fatal and non-fatal strokes (excluding transient ischaemic
attacks) reported in 10 RCTs (RR 0.86, 95% CI, 0.77–0.96, P ¼ 0.006, I2 ¼ 0%). A subgroup analysis of three
trials examining acute coronary syndrome patients found significant effects on all-cause (RR 0.75, 95% CI, 0.61–
0.91, P ¼ 0.005, I2 ¼ 0%) and CVD mortality (RR 0.74, 95% CI, 0.59–0.94, P ¼ 0.013, I2 ¼ 0%) with intensive
dosing. Applying an analysis of optimal information size on the primary analysis, we found that the evidence for
CHD death plus non-fatal MIs is conclusive. The evidence for CVD deaths alone is not yet conclusive.
Conclusions Available evidence suggests that intensive statin therapy reduces the risk of non-fatal events and may have a role in
reducing mortality.
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Introduction
HMG-CoA reductase inhibitors (statins) are currently the largest
selling prescription drug worldwide and may one day be widely
available over-the-counter (OTC),1 with a 10 mg tablet of simvas-
tatin already on sale OTC in the UK. Used predominantly for
cardiovascular disease (CVD) protection, there is widespread evi-
dence that statins provide protection across a wide range of popu-
lations with varying risk factors.2 –4 Given the broad populations
that statins have been evaluated in, statins have typically been com-
pared with placebo or commonly used care control groups.5 More
recently, there has been an increased focus on the potential that
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intensive lipid lowering with higher statin doses may have impor-
tant therapeutic benefits over commonly used doses.6 Large ran-
domized clinical trials (RCTs) have now evaluated varying doses
of intensive statins compared with moderate or lower doses.7
Clinicians have recognized that much of a statin’s therapeutic
effect is predominantly derived from its low-density lipoprotein
(LDL) lowering effects.2 As a result, there has been much discus-
sion within the cardiovascular community about providing inten-
sive, or higher, dosing of statins to achieve an increased
reduction in LDL, and subsequent clinical events.8– 10 The evidence
of this is mostly indirect.11 Five previous meta-analyses have been
completed, the last in 2010, including up to seven trials on clinical
endpoints.7,12– 15 Further RCTs are now available for the analy-
sis.16,17 We aimed to summarize the available data and determine
whether intensive statin dosing offers more favourable outcomes
to patients at risk of CVD events.
Methods
Eligibility criteria
We included any RCT of atorvastatin, fluvastatin, lovastatin, pitavasta-
tin, pravastatin, rosuvastatin, and simvastatin for CVD therapeutic
effects, as determined by the Canadian Compendium of Pharmaceuti-
cals and Specialties (2009).18 Studies had to compare a statin of mod-
erate dose with the same or another statin of higher dose and be of
.6 months duration. We did not include cerivastatin as it has been
withdrawn from the market due to serious adverse events. Studies
had to compare a statin to another statin and report on any of the fol-
lowing clinically important cardiovascular outcomes: All-cause mor-
tality; CVD mortality; coronary heart disease (CHD) death plus
non-fatal myocardial infarction (MI); fatal MI; non-fatal MI; strokes;
and non-CVD deaths. We excluded studies reporting only on surro-
gate outcomes (e.g. LDL and HDL levels) and follow-up studies
where randomization had been subverted.19 We additionally excluded
dose-ranging studies that were not head-to-head clinical evaluations.
Search strategy
In consultation with a medical librarian, we established a sensitive search
strategy (available from the authors upon request). Our search strategy
has been used in numerous published statin evaluations3–5,20,21 and uses
the MeSH term ‘Hydroxymethylglutaryl-CoA Reductase Inhibitors’ and
truncated ‘random*.’ We searched independently, in duplicate, the fol-
lowing 10 databases (from inception to 1 December 2010): MEDLINE,
EMBASE, Cochrane CENTRAL, AMED, CINAHL, TOXNET, Develop-
ment and Reproductive Toxicology, Hazardous Substances Databank,
Psych-info and Web of Science, databases that included the full text of
journals (OVID, ScienceDirect, and Ingenta, including articles in full text
from1700 journals since 1993). In addition, we searched the bibliogra-
phies of published systematic reviews2,5,21– 27 and health technology
assessments.28–30 Finally, we searched our own comprehensive rolling
database of statin trials, updated monthly. We also contacted the
authors of 5 RCTs for study clarifications,6,16,31 –33 and the authors of
two individual patient data meta-analysis of statins, which 5 head-to-head
trials and 21 inert controlled trials.2,7,27 Searches were not limited by
language, sex, or age.
Study selection
Two investigators (P.W., E.M.) working independently, in duplicate,
scanned all abstracts and obtained the full text reports of records,
that indicated or suggested that the study was a RCT evaluating
statin therapy on the outcomes of interest. After obtaining full
reports of the candidate trials (either in full peer-reviewed publication
or press article) the same reviewers independently assessed eligibility
from full text papers.
Data collection
The same two reviewers conducted data extraction independently using
a standardized pre-piloted form. The reviewers collected information
about the statin and type of interventions tested, the population
studied (age, sex, underlying conditions), the treatment effect on speci-
fied outcomes, absolute and proportion change in LDL, HDL, and total
cholesterol and the length of follow-up. Study evaluation included
general methodological quality features, including sequence-generation,
blinding, use of intent-to-treat analysis, % follow-up and allocation con-
cealment.34 We extracted data on the incidence of the following clinical
outcomes: all-cause mortality; CVD mortality; CHD death plus non-fatal
MI (includes any MI); fatal MI; non-fatal MI; fatal and non-fatal strokes; and
non-CVD deaths. We also abstracted data on adverse events including
increases in aspartate (AST) and alanine (ALT) aminotransferase, cre-
atine kinase (CK) levels beyond normal, and rhabdomyolysis (CK
level. 10 000 U/L). We entered the data into an electronic database
such that duplicate entries existed for each study; when the two
entries did not match, we resolved differences through discussion and
consensus.
Data analysis
In order to assess inter-rater reliability on inclusion of articles, we cal-
culated the Phi(f) statistic, which provides a measure of inter-observer
agreement independent of chance.35 We calculated the relative risk
(RR) and appropriate 95% confidence intervals (CIs) of outcomes
according to the number of events reported in the original studies
or sub-studies on an intent-to-treat basis. We pooled studies as an
analysis of all-statins combined using the DerSimonian–Laird random
effects method,36 which recognizes and anchors studies as a sample
of all potential studies, and incorporates an additional between-study
component to the estimate of variability.37 We also conducted an
optimal information size analysis to determine the strength of infor-
mation for our meta-analysis on the primary outcome of CVD death
and CHD plus non-fatal MI to determine the conservative number
of patients required to provide an authoritative answer of therapeutic
efficacy.38 Some argue that the reliability of the evidence in a
meta-analysis should only be established in rigorous decision-making
frameworks similar to those of Data Safety Monitoring Boards for
single RCTs. The concatenation of meta-analysis, and formal monitor-
ing boundaries (or stopping rules), such as the Lan–DeMets
alpha-spending monitoring boundary is analogous to group sequential
analysis in single RCTs.39,40 For the outcome of CV death, we con-
ducted a random effects cumulative meta-analysis assessing the effect
of high- vs. low-dose statin therapy on cardiovascular mortality risk.
The Lan–DeMets sequential monitoring boundary assumes a 5.5%
control event rate, 20% RR reduction, 80% power, and a two-sided
a ¼ 0.01. For the outcome of CHD plus non-fatal MI, the Lan–
DeMets sequential monitoring boundary assumes a 7.0% control
event rate, a 20% RR reduction, 80% power, and a two-sided a ¼
0.01). We conducted a subgroup analysis examining acute coronary
syndrome patients as this population has higher event rates and also
pleiotropic effects of statins may be more relevant than in stable
patients.41 We calculated numbers needed to treat for the outcome
of CHD death plus non-fatal MI across secondary prevention popu-
lations and CVD death for acute coronary syndrome patients using
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an approach recommended by Aaron and Fergusson that considers
events over person-time.42 E.J.M. and O.B. conducted all analyses.
Results
Figure 1 displays the flow diagram of study inclusion. We excluded
two studies that we inferred as non-intense vs. moderate
dosing.43,44 Two studies was published during peer review and
included.16,31 Additional data on one these, the SEARCH trial,
were available in unpublished format.45 In total, we identified 10
RCTs enrolling a total of 20 919 patients into intensive statin
dosages and 20 859 in moderate and lower dosages. The inter-
rater reliability for study inclusion was very good (f ¼ .0.9).
Table 1 displays the study characteristics and interventions.
Three trials included exclusively acute coronary syndrome
patients,6,16,46 one atherosclerosis33 and the remainder were sec-
ondary prevention patients.17,31,32,47–49 Women represented
24% of trial participants. The average age of included participants
was 55.5 years (SD 23), mean ages ranging from 56 to 74 years.
Trials followed patients for a mean 2.5 years (SD 2.13), ranging
from 0.5 to 6.7 years. The mean pre-trial LDL cholesterol was
122 mg/dL and ranged from 9748 to 150 mg/dL.
The reporting and quality of specific methodological trial com-
ponents were variable. Seven trials reported adequate methods of
randomization sequence generation.6,16,31,33,46–49 All studies
reported on who was blinded in the trial.6,16,17,31–33,46–49 Seven
reported allocation of study participants as concealed.6,16,17,31,33,46,47
Adequate follow-up was reported in all trials6,16,17,31–33,46–49 and
eight trials specifically reported using an intention-to-treat analy-
sis.6,16,31,33,46–49
Mortality
We included data from all 10 trials on incidence of all-cause
mortality.6,16,17,31– 33,46– 49 Our pooled analysis found a non-
significant trend towards decreased mortality (1791 vs. 1853
deaths, RR 0.92, 95% CI, 0.83–1.03, P ¼ 0.14, I2 ¼ 38%, see
Figure 2). The majority of deaths that occurred were CV deaths.
We pooled data from seven RCTs reporting CV deaths and
found a non-significant effect (1012 vs. 1086 deaths, RR 0.89,
95% CI, 0.78–1.01, P ¼ 0.07, I2 ¼ 34%, see Figure 3) on CVD mor-
tality.6,16,31,46– 49 Fatal MIs were poorly reported and available from
only two trials (164 vs. 299, RR 0.75, 95% CI, 0.41–1.35, P ¼
0.34).31,49 Similarly, non-CVD deaths were reported in only four
RCTs (565 vs. 581, RR 0.97, 95% CI, 0.87–1.09, P ¼ 0.65, I2 ¼
0%, see Supplementary material online, Figure S1).31,46,47,49 Only
one study reported on fatal strokes (57 vs. 67, RR 0.85, 95% CI,
0.59–1.20).31
Non-fatal myocardial infarction
We found a significant reduction in non-fatal MIs (935 vs. 1132, RR
0.82, 95% CI, 0.76–0.90, P ≤ 0.0001, I2 ¼ 0%) reported in five
RCTs.16,31,47 –49
Composite endpoints
When we pooled the composite endpoint of CHD death plus non-
fatal MI from nine trials,6,16,17,31– 33,46,47,49 we found a significant
protective effect of intensive statin dosages (1490 vs. 1660
deaths or MIs, RR 0.90, 95% CI, 0.84–0.96, P ≤ 0.0001, I2 ¼ 0%,
see Figure 4). We did not find a linear relationship between LDL
lowering effects and log RR for this outcome in a meta-regression
analysis (b coefficient 0.26, 95% CI, 20.15, 0.68, P ¼ 0.21). We
also found a significant reduction in the composite of fatal and non-
fatal strokes (excluding TIAs) reported in the 10 RCTs (576 vs.
669, RR 0.86, 95% CI, 0.77–0.96, P ¼ 0.006, I2 ¼ 0%, see Sup-
plementary material online, Figure S2).6,16,17,31– 33,46– 49 Applying a
weighted event rate number needed to treat (NNT), we estimate
that patients receiving intensive statin dosing for secondary preven-
tion have an NNT of 250 (95% CI, 162–735) to prevent a CHD or
non-fatal MI per year.
Acute coronary syndrome
We conducted a subgroup analysis examining three trials that
included patients with acute coronary syndrome.6,16,46 When
examining all-cause mortality, we found a reduction in RR 0.75
(95% CI, 0.61–0.91, P ¼ 0.005, I2 ¼ 0%).6,16,46 This was consistent
when examining CV deaths (RR 0.74, 95% CI, 0.59–0.94, P ¼
0.013, I2 ¼ 0%, see Supplementary material online, Figure
S3).6,16,46 This was not the case when examining CHD death
plus non-fatal MI (RR 0.85, 95% CI, 0.71–1.03, P ¼ 0.10, I2 ¼
32%).6,16,46 Nor did we demonstrate a significant effect of this sub-
group for non-CVD deaths (RR 0.98, 95% CI, 0.54–1.08, P ¼
0.96)46 or non-fatal MI (RR 0.55, 95% CI, 0.28–1.07, P ¼ 0.08).16
In no case, did we demonstrate an effect that was significantly
different than the overall pooled primary analyses. Applying a
weighted event rate NNT for CVD death, we estimate that 119
(95% CI, 63–1364) patients should be treated to prevent one
event per year.
Adverse events
We found no evidence of increased risk of cancers among inten-
sively treated patients compared with moderate treatment from
five trials (826 vs. 865, RR 0.95, 95% CI, 0.87–1.04, P ¼ 0.31,
I2 ¼ 0%).31,33,46,48,49 We also did not find an increased incidence
of rhabdomyolysis from six trials (16 vs. 7, RR 1.70, 95% CI,
0.56–5.19, P ¼ 0.34, I2 ¼ 20%).6,16,31,46–48 We did, however, find
an increase in the incidence of increased AST beyond normal,
reported in six trials (67 vs. 19, RR 3.15, 95% CI, 1.31–7.54, P ¼
0.01, I2 ¼ 53%),33,46–49 also observed with ALT increases (430
vs. 272, RR 1.57, 1.29–1.91, P ¼ 0.002, I2 ¼ 93%).16,31,33,46–49
We did not find a significant increase in risk of CK beyond
normal (203 vs. 100, RR 2.86, 95% CI, 2.02–4.04, P ≤ 0.001),
only reported in four trials.6,16,31,46 However, in one trial with high-
dose simvastatin, CK increases in 10 times the upper limit of
normal associated with myopathy were more common with sim-
vastatin 80 mg than simvastatin 40 mg (nine vs. one)46 and in one
trial of atorvastatin 80 mg, CK increases in two times the normal
limit associated with myopathy required discontinuation of the
drug in two patients.16
Optimal information size
We calculated the post hoc optimal information size based on
seven RCTs addressing CV death that assesses whether a sufficient
number of events have accrued to provide conclusive evi-
dence.6,16,31,46–49 For CV deaths the cumulative evidence is still
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inconclusive regarding this outcome as a further 4000 patients at
similar risk would need to be randomized. When we examined
the outcome of CHD plus non-fatal MI with data from nine
RCTs, we note that the evidence for CHD plus non-fatal MI
reduction is conclusive at the 80% power level.
Discussion
Our study found that intensive dosing of statins results in impor-
tant reductions in non-fatal events, including the composite of
CHD death plus non-fatal MI and the composite of fatal and non-
fatal strokes, in addition to non-fatal MIs alone. These benefits did
not appear to result in significantly reduced mortality for second-
ary prevention populations, although the direction of treatment
effect is almost consistently towards a benefit. We found an
increase in liver enzyme increases beyond normal associated
with intensive dosing in addition to possible important increases
in CK associated with rhabdomylosis. The SEARCH trial has exam-
ined the genotypic risks that may predict statin-induced myopathy,
a major step forward for patient-guided treatment.50 Within a sub-
group of acute coronary syndrome patients, intensive statin use
was associated with a reduced risk of all-cause and CVD mortality.
On balance, intensive dosing of statins appears to offer benefits to
patients and should be considered in light of patient history and
profile and possible adverse consequences.
There are strengths and limitations to consider in our analysis.
We extensively searched the literature and clarified our data
abstraction with study authors. We identified trials prior to their
publication (published during peer review of this article).31 We
updated the results of previous meta-analyses6,7,13,14 and included
additional RCTs. We applied the optimal information size and
found that conclusive evidence for the benefit of CHD plus non-
Figure 1 Flow diagram of included studies.
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Table 1 Study characteristics
Study Year Patient status/
condition at
baseline
Treatment
comparisons
(mg/day)
Follow
up,
years
Randomized
individuals
Age,
mean,
years
Men, % Prior
CHD, %
Diabetes, % Hyper
tension, %
Current
smokers, %
Baseline, mean
mg/dL (change)
LDL HDL
A–Z46 2004 Acute coronary
syndrome
S40–80 vs. S0–
20
2 4497 61 76 100 24 50 41 111 (237) 39 (20.7)
IDEAL47 2005 CHD A80 vs. S20 4.8 8888 62 81 100 12 33 21 121 (222) 46 (20.5)
PROVE-IT6 2004 Acute coronary
syndrome
A80 vs. P40 2 4162 58 78 100 18 50 37 106 (233) 39 (0.65)
REVERSAL33 2004 Atherosclerotic A80 vs. P40 1.5 654 56 72 100 19 69 26 150 (232) 43 (0.7)
TNT48 2005 CHD A80 vs. A10 4.9 10001 61 81 100 15 54 13 98 (222) 47 (0)
Vascular
basis.32
2005 CHD A80 vs. L5 1 199 — 86 100 16 64 0 148 (233) 45 (7.0)
SAGE49 2007 CHD A80 vs. P40 1 893 72 69 100 23 65 6 147 (230) 46 (11)
Yu et al.17 2007 CHD A80 vs. A10 0.5 112 66 82 100 28 51 44 116 (239) 50 (26)
Colivicchi
et al.16
2010 Acute coronary
syndrome
A80 vs. A20/40 1 290 74 52 100 71 89 — 126 (264) 40 (–)
SEARCH31 2008 CHD S80 vs. S20 6.7 12064 — 83 100 — — — 97 (214) 39 (–)
A–Z, Aggrastat and Zocar; IDEAL, incremental decrease in events through aggressive lipid lowering; PROVE-IT TIMI, pravastatin or atorvastatin evaluation and infection therapy–thrombolysis in myocardial infarction 22; REVERSAL, reversal of
atherosclerosis with aggressive lipid lowering; SAGE, study assessing goals in the elderly; SEARCH, study of the effectiveness of additional reductions in cholesterol and homocysteine; TNT, treating to new targets; vascular basis, Vascular Basis
for the Treatment of Myocardial Ischaemia Study.
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fatal MI risk reductions is robust, but that the impact of intensive
dosing on any cause of mortality was less so. Limitations of our
analysis include that we are employing study level data and an indi-
vidual patient data may provide stronger inferences on the LDL
lowering effects of intensive vs. moderate dosing. The Cholesterol
Treatment Trialists Collaboration (CTTC)2 have updated their
analysis with the addition of the SEARCH trial and found a signifi-
cant association between LDL reduction and vascular events, data
unavailable through publications.7 A limitation associated with any
meta-analysis is the conclusiveness of an analysis, based on the ade-
quacy of events. Our analysis used event rates at the conclusion of
each trial and did not adjust for time effects, as a meta-analysis
using time-to-event data may permit. In our analysis, we con-
sidered statins as a class of drugs, expecting that each drug
exerts a similar therapeutic effect. We previously examined this
in statin vs. placebo trials.51 It is possible that there are differing
effects between statins when using intensive dosing. Several of
the trials did not report the component endpoints in the individual
trials, leaving some of our analyses underpowered. An analysis that
examined the impact of unreported outcomes on summary
estimates from Cochrane reviews found overestimation of
summary estimates when outcomes were inadequately contribut-
ing to the analysis.52 It is likely that in some of our analyses, we
are also experiencing bias, but cannot infer the direction of that
bias. Our analysis of CVD mortality is inconclusive, according to
the trial sequential analysis, and has comparatively wide confidence
intervals for this major endpoint, and demonstrates that data on a
further 4000 randomized patients would be needed to provide
robust evidence. Our analysis only examined statins and therefore
did not examine whether there is any benefit in using other agents
(nicotinic acid, fibrates, ezetimibe) as add-on treatments to a statin
to achieve additional LDL-C lowering and possible reduction in
events.
Our analysis should be interpreted in the context of previous
meta-analyses. Five previous meta-analyses have aimed to deter-
mine the effectiveness of intensive vs. moderate dosing.7,12– 15
We have added two additional studies. Regardless, our study is
in keeping with previous analysis findings of no significant reduction
in mortality although there seems a favourable trend for intensive
dosing of statins. A recent individual patient data meta-analysis by
Figure 2 Forest plot of all-cause mortality.
Figure 3 Forest plot of cardiovascular death mortality.
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Murphy et al. found a significant decrease in acute coronary patient
mortality when combining the PROVE-IT and the A–Z trials invol-
ving patients with acute coronary syndrome (0.77, 95% CI, 0.63–
0.95, P ¼ 0.015).53 We also conducted an analysis of exclusively
acute coronary syndrome patients, involving three RCTs, and
found a significant reduction both all-cause and CVD mor-
tality.6,16,46 Event rates are higher in the short period after an
acute coronary syndrome than more stable disease.54 It is possible
that the effect detected is because acute coronary syndrome trials
have better power, due to larger event rates, than secondary pre-
vention trials. It is also possible that pleiotropic effects of statins
might be more relevant in acute coronary syndrome than in
stable disease.54
Clinicians should take note that our analysis found important
reductions in non-fatal events and may not translate to reduced
mortality. Along with this finding is the increased risk of adverse
events associated with hepatic enzyme elevations and possible
liver damage. However, a longitudinal analysis of the Greek Ator-
vastatin and Coronary Heart Disease Evaluation (GREACE) Study
evaluated long-term outcomes of those randomized to moderate
dose atorvastatin vs. placebo and found more favourable liver out-
comes in statin than placebo patients.55 One of our most concern-
ing findings was an increased risk for rhabdomyolysis associated
with intensive simvastatin dosing in the A–Z trial46 and also in
the SEARCH trial.31 Given that this is a relatively rare event and
was inadequately reported across trials, this provides an early infer-
ence to continually examine for serious myopathy associated with
intensive dosing. While many physicians consider all statins to be
the same, compelling evidence of differential adverse events associ-
ated with the now withdrawn statin, cerivastatin, suggest that not
all statins may have the same therapeutic or adverse event profiles.
Notably, the evidence for cerivastatin harms was drawn from post-
marketing surveillance.56 Physicians suspicious of myopathy should
consider CK measurements, statin dosage reduction, discontinu-
ation, and rechallenge; and treatment alternatives, such as
extended-release fluvastatin, low-dose, or alternate-day
rosuvastatin.57
There is considerable interest in combining statin therapy with
emerging drug developments. The problem with current combi-
nation therapies involving, for example, simvastatin and ezetimibe
or statins with fibrates is that, although they are likely to
improve reductions in LDL-targets, the results from only a few
clinical trials have yielded consistently disappointing results in
terms of major clinical endpoints. More evidence on this is
expected with ongoing RCTs.58
In conclusion, our study found no significant improvement in
mortality associated with intensive statin use, but did find a
reduction in non-fatal events. In a subgroup of acute coronary syn-
drome patients, intensive dosing reduced mortality. For patients at
sufficient risk for a cardiovascular event, the decision on which
agent to use and at what dose remains one to be agreed jointly
between the patient and the treating physician after a discussion
on relative benefits and risks.
Supplementary material
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online.
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